Amyloid β-Protein (16-20) |
Catalog No.GA20740
One-Click Copy Product Info
|
Amyloid β-Protein (16-20) is a five-amino acid fragment of the amyloid-β protein.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 153247-40-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Amyloid β-Protein (16-20) is a five-amino acid fragment of the amyloid-β protein. Amyloid β-Protein (16-20) disrupts the formation of β-sheet structures by competitively binding to the hydrophobic core region of the Aβ protein[1-2]. Amyloid β-Protein (16-20) can be used in research related to the pathological mechanisms of Alzheimer's disease and drug screening[3-4].
In vitro, Amyloid β-Protein (16-20) (100nM) was applied to rat striatal and hippocampal synaptosomes for 1 hour. Amyloid β-Protein (16-20) did not increase the percentage of apoptotic signals nor alter the survival rate of the synaptosomes[5]. Amyloid β-Protein (16-20) (100µg/mL) was used to treat differentiated human SH-SY5Y neuroblastoma cells (induced by retinoic acid and brain-derived neurotrophic factor) overnight, resulting in a small amount of cell death. Treatment of human red blood cells with Amyloid β-Protein (16-20) (100µg/mL) for 3 hours caused hemolysis[6].
References:
[1] Chandra Saha P, Das RS, Chatterjee T, et al. Supramolecular β-Sheet Forming Peptide Conjugated with Near-Infrared Chromophore for Selective Targeting, Imaging, and Dysfunction of Mitochondria. Bioconjug Chem. 2020 May 20;31(5):1301-1306.
[2] Waugh ML, Wolf LM, Moore KA, et al. Rationally Designed Peptoid Inhibitors of Amyloid-β Oligomerization. Chembiochem. 2024 Jul 2;25(13):e202400060.
[3] Kino R, Araya T, Arai T,et al. Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif. Bioorg Med Chem Lett. 2015 Aug 1;25(15):2972-5.
[4] Niu L, Liu L, Xi W, et al. Synergistic Inhibitory Effect of Peptide-Organic Coassemblies on Amyloid Aggregation. ACS Nano. 2016 Apr 26;10(4):4143-53.
[5] Trebesova H, Olivero G, Marchi M, et al. The Anti-Aggregative Peptide KLVFF Mimics Aβ1-40 in the Modulation of Nicotinic Receptors: Implications for Peptide-Based Therapy. Biomedicines. 2022 Sep 8;10(9):2231.
[6] Roytrakul S, Jaresitthikunchai J, Phaonakrop N, et al. Secretomic changes of amyloid beta peptides on Alzheimer's disease related proteins in differentiated human SH-SY5Y neuroblastoma cells. PeerJ. 2024 Jul 17;12:e17732.
| Cell experiment [1]: | |
Cell lines | Human SH-SY5Y neuroblastoma cells |
Preparation Method | SH-SY5Y cells were differentiated into mature neurons using retinoic acid (RA) and brain-derived neurotrophic factor (BDNF). The differentiated cells were then treated with Amyloid β-Protein (16-20) at a concentration of 100μg/mL and incubated overnight. |
Reaction Conditions | 100μg/mL; overnight. |
Applications | Amyloid β-Protein (16-20) treatment resulted in 4.21% cell death in the differentiated SH-SY5Y cells, showing the least cytotoxic activity among the tested peptides. |
References: | |
| Cas No. | 153247-40-6 | SDF | |
| Formula | C35H52N6O6 | M.Wt | 652.84 |
| Solubility | H2O : 33.33 mg/mL (51.06 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5318 mL | 7.6588 mL | 15.3177 mL |
| 5 mM | 306.4 μL | 1.5318 mL | 3.0635 mL |
| 10 mM | 153.2 μL | 765.9 μL | 1.5318 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)